India Globalization Capital’s IGC-AD1 for Alzheimer’s disease (AD) symptoms saw its Phase Transition Success Rate (PTSR) surge 15 points to 73% after completing its Phase I trial. The PTSR update occurred on 25 June after IGC announced on 23 June it completed the final cohort of its 12-patient Phase I. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The multiple ascending dose Phase I trial (NCT04749563) has a primary endpoint assessing safety, and changes in the Neuropsychiatric Inventory (NPI) scale as a secondary efficacy endpoint. IGC-AD1, which uses the psychoactive component of cannabis THC, is designed to help improve the lifestyle of patients with AD.

Phase I completion also generated a modest 2-point bump in the drug’s Likelihood of Approval (LoA), which rose to 9%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

IGC has a market cap of $67.6m.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.